Trabectedin

Catalog No.S7758 Synonyms: Ecteinascidin 743, ET-743

For research use only.

Trabectedin (Ecteinascidin 743, ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata with antitumour activity. Trabectedin binds to the N2 of guanine in the minor groove, causing DNA damage and affecting transcription regulation in a promoter- and gene-specific manner.

Trabectedin Chemical Structure

CAS No. 114899-77-3

Selleck's Trabectedin has been cited by 1 Publication

Purity & Quality Control

Related Other Products

Biological Activity

Description Trabectedin (Ecteinascidin 743, ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata with antitumour activity. Trabectedin binds to the N2 of guanine in the minor groove, causing DNA damage and affecting transcription regulation in a promoter- and gene-specific manner.
In vitro

Trabectedin can block EWS-FLI1 transcription factor activity, suppress Werner syndrome protein (WRN) expression and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. <sup><a class="sref" href="#s_ref">[1]</a></sup><sup><a class="sref" href="#s_ref">[3]</a></sup>

In vivo

In Tumor-Bearing Mice, trabectedin does not have an impact on the functional activity of MDSC but does significantly reduce the number of Ly6C<sup>high</sup> cells, the most suppressive subset. <sup><a class="sref" href="#s_ref">[4]</a></sup>

Protocol (from reference)

Cell Research:

[3]

  • Cell lines: Ewing sarcoma cells
  • Concentrations: 10 nM
  • Incubation Time: 18 h
  • Method:

    RNAiMax Lipofectamine (4.5 mL per well in a 6-well dish) was added to siRNA targeting the EWS-FLI1 breakpoint site II, complexed, combined with cells, and incubated for 36 to 48 hours before collection for Western blot analysis.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 761.84
Formula

C39H43N3O11S

CAS No. 114899-77-3
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04979442 Recruiting Drug: RAIN-32|Drug: Trabectedin Dedifferentiated Liposarcoma Rain Therapeutics Inc. July 14 2021 Phase 3
NCT04008238 Recruiting Drug: Trabectedin Soft Tissue Sarcoma Adult|Undifferentiated Pleomorphic Sarcoma|Epithelioid Sarcoma|Solitary Fibrous Tumors|Hemangioendothelioma|Desmoplastic Round Cell Tumor|Synovial Sarcoma Institut Bergonié January 6 2020 Not Applicable
NCT03884972 Withdrawn Drug: Trabectedin|Drug: Venetoclax Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) June 18 2019 Phase 1
NCT03437070 Withdrawn Drug: Trabectedin|Drug: Doxorubicin|Drug: Olaratumab Leiomyosarcoma University of Miami|Janssen Scientific Affairs LLC June 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Trabectedin | Trabectedin supplier | purchase Trabectedin | Trabectedin cost | Trabectedin manufacturer | order Trabectedin | Trabectedin distributor